
    
      All patients will receive combination therapy to include piperacillin-tazobactam 400
      mg/kg/day (based on piperacillin component, actual body weight) not to exceed 16 grams and
      tobramycin 12 mg/kg/day extended interval dosing (once daily). Patients randomized to the
      continuous infusion group will receive a one-time loading dose of 100 mg/kg over 30 minutes
      followed immediately by initiation of the continuous infusion.

      Other antibiotics with activity against Pseudomonas aeruginosa are not allowed. Patients may
      receive an antibiotic for treatment of Staphylococcus aureus if deemed appropriate.

      Other treatments for pulmonary exacerbation of cystic fibrosis will be left up to the control
      of the treating physician. Patients will receive a total of 14 days of therapy. If deemed
      appropriate, patients may be discharged to home where they will continue to receive blinded
      treatment via an infusion pump. Patients will be evaluated after completing their 14 day
      course of antibiotics (end of therapy).
    
  